PCSK9 and atherosclerosis: There were similar results in the Studies of PCSK9 Inhibition and the Reduction of Vascular Events (SPIRE) trials, though the relative percentage of ASCVD events was lower than FOURIER and ODYSSEY Outcomes (2.1% in SPIRE 1 at median followup of 7 months and 3.4% in SPIRE 2 at median followup of 12 months) (16) In the landmark statin trials where LDL-C lowering reduced the relative risk of ASCVD, participants who received statins still exhibited a significant residual cardiovascular risk.